Advanced Biomed Inc - ADVB Forward Price-to-Revenue Multiple
Advanced Biomed Inc (ADVB) is protected by biomarker patents and strict regulatory oversight, as confirmed by the forward P/S trajectory on the GURU.Markets chart, where the metric is fixed at 0.00. The business relies on the scalable sale of disposable cartridges alongside stable equipment costs. Additionally, the company is implementing software robots to accelerate the processing of diagnostic data arrays.
Summary analytical data breakdowns for advanbiomed.com (ADVB)
- current price and projected stock value:
- issuer market value details:
- business book valuation details:
- business debt structure and liquidity details:
- financial results and valuation multiples details:
ADVB - Company Net Income|Projected Future Earnings Advanced Biomed Inc|ADVB - Business Payback Period|Future Price to Earnings Advanced Biomed|ADVB - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ADVB|ADVB - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Advanced Biomed|ADVB - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth advanbiomed.com|ADVB - Earnings per share growth this year|Expected earnings per share growth for next year Advanced Biomed Inc
- total revenue and sales volume data:
Initial company analysis:Advanced Biomed Corp ADVB
Cancer diagnostic automation via Advanced Biomed Inc (ADVB) microfluidic platforms determines the potential for revenue scaling, which is reflected in the company's forward P/S valuation. This indicator correlates current market capitalization with projected sales volume, allowing investors to differentiate fundamental undervaluation of a mature business from a systemic slowdown in expansion and the risk of invested capital stagnation.
Competitor analysis for Advanced Biomed Inc
Forward P/S Multiple ONC (BeiGene)|HALO: Market Cap to Projected Revenue|RVMD: Forward Price-to-Revenue Multiple|AAPG: Price-to-Projected Revenue Ratio|CGON: Forward P/S Multiple|urogen.com (URGN) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Bicara Therapeutics|Market Cap to Projected Revenue PSNL (Personalis Inc)|Forward P/S Multiple ERAS|Forward Price-to-Revenue Multiple Delcath Corp DCTH|Forward P/S Multiple YMAB (Y-mAbs Therapeutics)|aurabiosciences.com (AURA) - Market Cap to Future Revenue Ratio|Candel - Forward P/S Multiple|ARAY (Accuray Inc) - Market Cap to Projected Revenue|SLS (sellaslifesciences.com) - Forward Price-to-Revenue Multiple|Actuate Therapeutics Inc - Forward Price to Sales|CTOR (Citius Oncology, Inc.) - Forward P/S Multiple|Price-to-Projected Revenue Ratio HURA|Forward P/S Multiple TARA|Market Cap to Expected Sales Ratio Fate Therapeutics Inc|Price-to-Projected Revenue Ratio Aadi Bioscience WHWK|TScan Therapeutics Inc (TCRX) - Market Cap to Future Revenue Ratio|CSBR - Price-to-Projected Revenue Ratio|XBiotech Inc. (XBIT) - Forward Price-to-Revenue Multiple|CVM: Forward P/S Multiple|Market Cap to Future Revenue Ratio OS Therapies Inc. (OSTX)|RADX (Radiopharm Theranostics Limited) - Forward P/S Multiple|Market Cap to Projected Revenue ARTV (Artiva)|Forward Price-to-Revenue Multiple ANL (Adlai Nortye Ltd.)|VERU (verupharma.com) - Forward Price to Sales|Forward P/S Multiple TPST (Tempest Therapeutics, Inc.)|Market Cap to Expected Sales Ratio Xilio Therapeutics Inc (XLO)|RENB - Price-to-Projected Revenue Ratio|MURA (Mural Oncology plc) - Market Cap to Projected Revenue|KAPA: Forward P/S Multiple|Forward Price-to-Revenue Multiple OnKure Therapeutics|GDTC (CytoMed Therapeutics Ltd) - Forward P/S Multiple|Forward P/S Multiple Curis Corp|Forward P/S Multiple APLM|Tharimmune Corporation - Market Cap to Projected Revenue|Genprex, Inc. - Forward Price-to-Revenue Multiple|Calidi Biotherapeutics Inc. - Price-to-Projected Revenue Ratio|Sunshine Biopharma, Inc. - Forward P/S Multiple|XBIO: Price-to-Projected Revenue Ratio|SLRX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Kitov Pharma|AONC (American Oncology Network Inc) - Forward P/S Multiple|Forward P/S Multiple beigene.com|Price-to-Projected Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|elevationoncology.com - Market Cap to Projected Revenue|Forward P/S Multiple ICAD (iCAD)|IKNA - Forward Price-to-Revenue Multiple|Notable Labs, Ltd. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Viracta Therapeutics|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Inc - Forward Price to Sales|Forward Price-to-Revenue Multiple AAPGV
